CSPC Innovation Pharmaceutical

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026

CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced today the initiation and public registration of...

Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Fineline Cube Jun 22, 2026

CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group (HKG: 1093), has released...

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China